These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34656651)

  • 1. Disease modifying therapies III: Novel targets.
    Vijiaratnam N; Foltynie T
    Neuropharmacology; 2021 Dec; 201():108839. PubMed ID: 34656651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis.
    Manfready RA; Goetz CG; Keshavarzian A
    Int Rev Neurobiol; 2022; 167():81-99. PubMed ID: 36427960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers.
    Cheslow L; Snook AE; Waldman SA
    Biomark Med; 2021 Jun; 15(8):597-608. PubMed ID: 33988462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targeted therapies for Parkinson's disease.
    Ntetsika T; Papathoma PE; Markaki I
    Mol Med; 2021 Feb; 27(1):17. PubMed ID: 33632120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status and future directions of clinical trials in Parkinson's disease.
    Söderbom G
    Int Rev Neurobiol; 2020; 154():153-188. PubMed ID: 32739003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress towards therapies for disease modification in Parkinson's disease.
    Vijiaratnam N; Simuni T; Bandmann O; Morris HR; Foltynie T
    Lancet Neurol; 2021 Jul; 20(7):559-572. PubMed ID: 34146514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical approaches to the development of a neuroprotective therapy for PD.
    Olanow CW; Kieburtz K; Katz R
    Exp Neurol; 2017 Dec; 298(Pt B):246-251. PubMed ID: 28622912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease.
    Alfonsetti M; Castelli V; d'Angelo M
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
    Stephenson D; Badawy R; Mathur S; Tome M; Rochester L
    J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.
    Liang Y; Cui L; Gao J; Zhu M; Zhang Y; Zhang HL
    Mol Neurobiol; 2021 Aug; 58(8):3745-3758. PubMed ID: 33825149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
    Evans JR; Barker RA
    Expert Opin Pharmacother; 2011 Jun; 12(8):1249-58. PubMed ID: 21345151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of the gut microbiota in Parkinson's disease].
    Verugina NI; Levin OS; Lyashenko EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10. Vyp. 2):86-91. PubMed ID: 34870920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options.
    Wang Q; Luo Y; Ray Chaudhuri K; Reynolds R; Tan EK; Pettersson S
    Brain; 2021 Oct; 144(9):2571-2593. PubMed ID: 33856024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gut microbiome in Parkinson's disease: A culprit or a bystander?
    Keshavarzian A; Engen P; Bonvegna S; Cilia R
    Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-gut-microbiota axis in Parkinson's disease.
    Mulak A; Bonaz B
    World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of defining preclinical or prodromal Parkinson's disease.
    Olanow CW; Obeso JA
    Mov Disord; 2012 Apr; 27(5):666-9. PubMed ID: 22508285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches.
    Colombo D; Pnevmatikou P; Melloni E; Keywood C
    Expert Rev Neurother; 2020 Oct; 20(10):1047-1064. PubMed ID: 32758042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of modifying disease progression in prediagnostic Parkinson's disease.
    Salat D; Noyce AJ; Schrag A; Tolosa E
    Lancet Neurol; 2016 May; 15(6):637-48. PubMed ID: 26993435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.